Despite Shanghai Labway Clinical Laboratory's strong revenue growth, investors may be skeptical about its ability to maintain recent growth rates, potentially pressuring the P/S ratio. The risk of a price decline seems low, but future revenue fluctuations are a concern for investors.
兰卫医学股票讨论区
暂无评论